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Abstract We have synthesized and fully characterized the NK2
receptor antagonist nepadutant and its by-products using nuclear
magnetic resonance (NMR) and restrained molecular dynamics.
The agent consists of an active bicyclic hexapeptide combined
with a sugar residue. Analysis of the high-performance liquid
chromatogram and the mass spectroscopy spectra yields traces of
three by-products with the same molecular weight as the main
product. The conformation of the molecules in the bicyclic
hexapeptide segment, the active region, is well defined, whereas
the sugar moiety is disordered. For the peptide region of
nepadutant and all of its by-products, the NMR observables
can be described by a single backbone conformation, more
specifically a LI, LII-turn arrangement. The active dipeptide unit
Trp^Phe occupies the i+1 and i+2 position of a LI-turn. The by-
product profile is characterized by different forms of sugars
which are caused mainly by isomerization in the process of ring
opening. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Tachykinins are a family of neuropeptides widely distrib-
uted in the mammalian central and peripheral nervous sys-
tems, which produce a wide range of biological e¡ects through
the stimulation of three distinct receptor subtypes NK1 to
NK3 [1]. Among the three natural mammalian tachykinins,
substance P displays the highest a⁄nity for the NK1 receptor,
Neurokinin A for the NK2 receptor and Neurokinin B for the
NK3 receptor. Neurokinin A has links to chronic diseases in
the gastrointestinal, respiratory and genitourinary tracts [2].
The development of novel drugs based on peptide and non-
peptide antagonists of the NK2 receptor may provide new
opportunities for the therapy of diseases like asthma, in£am-
matory bowel disorders, rheumatoid arthritis, pain and psy-
chiatric disorders [3].
The development of peptide-based NK2 receptor antago-
nists proceeded starting from Neurokinin A via linear pep-
tides, monocyclic pseudopeptides extending to bicyclic pep-
tides [4^7]. The bicyclic glyco-hexapeptide nepadutant,
cyclo{[Asn(L-D-GlcNAc)-Asp-Trp-Phe-2,3-diamino propionic
acid (Dpr)-Leu] cyclo(2L-5L)}, is such an e¡ective and selec-
tive tachykinin NK2 receptor antagonist. The pharmacologi-
cal pro¢le of nepadutant has been the subject of extensive
research [8,9]. It was found that nepadutant showed negligible
binding a⁄nity at 50 di¡erent receptors, including tachykinin
NK1 and NK3 receptors and ion channels. Otherwise, nepa-
dutant competitively binds with high a⁄nity to the human
NK2 receptor, displacing radiolabelled 125I-Neurokinin A.
Therefore, it is a suitable candidate for clinical testing in hu-
mans, especially for studying the pathophysiological signi¢-
cance of tachykinin NK2 receptors. Defacto, nepadutant is
currently in phase II clinical trials and was selected as refer-
ence compound for further developments.
Nepadutant is a glycosylated analogue of the potent, selec-
tive, conformationally constrained NK2 receptor antagonist
MEN10627 (cyclo{(Met-Asp-Trp-Phe-Dpr-Leu) cyclo(2L-
5L)}) [6,7]. The introduction of the sugar moiety did not pro-
duce major changes in the a⁄nity pro¢le of this antagonist as
compared to MEN10627, but markedly improved its in vivo
potency and duration of action [10]. The by-product pro¢le of
nepadutant after ¢nal puri¢cation is reproducibly character-
ized by the presence of three by-products MEN11420A (cy-
clo{[Asn(2-acetamido-2-deoxy-L-D-mannopyranose)-Asp-Trp-
Phe-Dpr-Leu] cyclo(2L-5L)}), MEN11420C (cyclo{[Asn(2-
acetamido-2-deoxy-L-D-glucofuranose)-Asp-Trp-Phe-Dpr-Leu]
cyclo(2L-5L)}) and MEN11420D (cyclo{[Asn(2-acetamido-2-
deoxy-K-D-glucopyranose)-Asp-Trp-Phe-Dpr-Leu] cyclo(2L-
5L)}) in a range between 0.1 and 1.5%. Our aim was the
complete solution structure elucidation of nepadutant and
mainly of its by-products for quali¢cation as a new drug
substance. The structure determination by combined nuclear
magnetic resonance (NMR) spectroscopy and restraint molec-
ular dynamics calculations is described. A detailed insight into
the 3D structures of the synthetic tachykinin NK2 receptor
antagonist, nepadutant, and the attendant unavoidable by-
products, is given.
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2. Materials and methods
2.1. Synthesis and isolation
Nepadutant was synthesized by the coupling of the peptide precur-
sor MEN11282 (cyclo{(Asp-Asp-Trp-Phe-Dpr-Leu) cyclo(2L-5L)})
with L-D-2-acetamido-2-deoxy-glucopyranosylamine. MEN11282 was
synthesized by classical peptide synthesis procedures in solution using
the tert-butyloxycarbonyl (Boc), benzyloxycarbonyl- (Z) groups for
N-terminal and the methyl ester group (OMe) for the C-terminal
protection.
The main and minor components of nepadutant were isolated by
reversed phase HPLC procedures in acetonitrile/water systems [11].
The by-products of nepadutant could be isolated with a purity of
98.8% MEN11420A, 84.6% MEN11420C and 89.6% MEN11420D
for structure elucidation. The identity of the isolated samples was
proved by analytical HPLC of MEN11420 with spiked amounts of
the isolates. Mass spectrometric analyses were performed on a VG
Quattro mass spectrometer (Altrincham, UK) equipped with standard
electrospray (ES) ion source.
2.2. NMR spectroscopy
Samples for NMR spectroscopy were prepared by dissolving 5 mg
of the reference compound nepadutant and 1^2 mg of isolated
MEN11420A, MEN11420C and MEN11420D in 0.75 ml of
DMSO-d6 in a 5 mm sample tube (Wilmad, NJ, USA).
2D spectra were recorded at 600 MHz on a Bruker AMX 600
spectrometer with a spectral width of 7250 Hz for protons in both
dimensions. Data matrices typically consisted of 2048 complex points
in F2 for each of the 512 F1 increments, the data being zero-¢lled to a
2048U1024 complex matrix before transformation. The apodization
functions used in processing were 90‡ shifted sine-bell squared for all
2D experiments. The spectra were processed using the XWINNMR
program (Bruker, Germany) on a Silicon Graphics O2 workstation.
ROESY crosspeaks were integrated by the AURELIA software
(Bruker, Germany) including o¡set correction according to Bull
[12]. Chemical shifts and coupling constants were evaluated from
complete simulation of 1H-NMR spectra with WIN-DAISY
(Bruker-Franzen, Germany). Selected parameters for 2D-NMR ex-
periments: TOCSY, mixing time 20 and 70 ms, NS = 16^40; ROESY,
mixing time 120, 150, 180 ms, NS = 64^80; NOESY, mixing time 50,
120, 200, 400 ms, NS = 40^80.
2.3. Molecular modelling
The data derived from NMR spectra were analyzed via in vacuo
restrained molecular dynamics simulations (rMD) on an IRIS Indigo
computer using XPLOR [13]. At ¢rst 50 starting structures were ini-
tially generated by randomizing the atom coordinates of a manually
constructed structure followed by energy minimization and rMD at
300 K. The L-con¢guration of the amino acids Leu, Phe and Asp is
con¢rmed by racemization investigations of nepadutant and
MEN11420A^D. In order to ¢nd starting conformations re£ecting
as much as possible the restrained geometry, we applied another
run with a strong force constant k(NOE) = 50.0 kcal/(mol A2).
All structures were subjected to a subsequent rMD protocol in
conjunction with a simulated annealing procedure. We carried out
an rMD simulation at 1000 K under non-bound conditions followed
by cooling to 100 K. The seven structures with the lowest total energy
were than used for an additional rMD simulation over 90 ps at 300 K.
All force constants were set to 1. The structures were ¢nally relaxed
with an energy minimization.
3. Results
3.1. By-product pro¢le
The by-product pro¢le of the crude peptide nepadutant
before ¢nal puri¢cation is reproducible characterized by the
presence of the impurities MEN11282 and MEN11295 (cy-
clo{(Asn-Asp-Trp-Phe-Dpr-Leu) cyclo(2L-5L)}) known to be
induced by the way of syntheses in a range up to 3% and the
by-products MEN11420A, MEN11420C and MEN11420D in
a range between 0.1 and 1.5%. MEN11282 is the starting
material of the last coupling step and MEN11295 is a by-
product of the last coupling step. Both impurities can be
quantitatively separated by the ¢nal puri¢cation.
After the ¢nal puri¢cation, beside the desired compound
also the by-products MEN11420A, MEN11420C and
MEN11420D are present in all batches of nepadutant with
values of up to 0.8, 1.0 and 1.5%, respectively. The analysis
of the distribution of these by-products in the fractions of the
¢nal preparative HPLC puri¢cation demonstrates the impos-
sibility of their quantitative separation (Fig. 1). Nevertheless,
the distribution of the mentioned by-products in the main
peak of the nepadutant puri¢cation indicates an enrichment
of the by-product MEN11420A in the pre-fractions and of the
by-products MEN11420C and MEN11420D in the post-frac-
tions. Further accumulation of those materials by repeated re-
chromatography was expected to provide the pure by-prod-
ucts for structure elucidation. This procedure permits us to
carry out a detailed conformational analysis for all four com-
pounds.
3.2. Structural characterization
The bicyclic NK2 receptor antagonist nepadutant consists
of two characteristic structure units of di¡erent chemical na-
ture. These are the peptidic moiety containing the pharmaco-
logically active amino acid sequence and the solubility-in-
creasing carbohydrate moiety.
Mass spectra were measured for all four compounds. Inter-
estingly, the molecular mass of the three by-products and of
nepadutant was determined to be (MH) at m/z 947. The
mass spectra show practically identical fragmentation pat-
terns. The MS/MS spectrum of m/z 947 gives the ion at m/z
727, corresponding to the peptide core and the ion at m/z 204
corresponding to the sugar moiety. It was found that the MS,
MS/MS and MS3 spectra of the by-products are almost super-
imposable to that of nepadutant. The most relevant di¡eren-
ces were found in the MS/MS spectra of the ion m/z 204, in
which the masses of the fragments are the same, but their
relative abundances vary slightly. This reinforces our hypoth-
esis, that the structural di¡erences between nepadutant and its
by-products are located in the sugar moiety.
3.3. Structural analysis of the peptide moiety
Evaluation of the NOESY/ROESY spectra and coupling
constants of the four compounds, resulted in very similar
spectral information. It is clear evidence for the close relation-
ship of the peptide conformations between nepadutant and its
Fig. 1. Distribution of nepadutant (MEN11420) and its by-products
in the preparative RP-18 chromatography.
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by-products. Therefore, we will only discuss the conforma-
tional analysis of nepadutant and MEN11420D, the most
predominant by-product.
The 1H-NMR spectra of nepadutant and MEN11420D
show only one set of resonances with very broad resonance
lines for three amino acid residues at 298 K. Changing mea-
surement conditions, especially the raise of the temperature to
333 K leads to spectra with shape lines and well resolved NH
resonances. The results of the chemical shift assignments and
coupling constants for the peptide moieties are shown in Ta-
ble 1.
The temperature coe⁄cients of the NH chemical shifts are
in both cases very small for amino acids Asp2 and Dpr5,
pointing to the involvement of Asp2NH and Dpr5NH in a
hydrogen bond. With regard to the structure of other cyclic
hexapeptides, we could expect a peptide conformation with
two L-turns each stabilized by a COiCNHi3 hydrogen
bond [14]. Here, Asp2 and Dpr5 act as hydrogen bond donors
as well as acceptors, resulting in the hydrogen bonds
Asp2COCDpr5NH and Dpr5COCAsp2NH. We additional-
ly observed a small temperature coe⁄cient for Phe4NH, which
can be explained by an interaction between Phe4NH with the
rigid side chain carbonyl function of Asp2, involved in the side
chain linkage.
The medium range NOEs (Table 2) and dihedrals P derived
from the 3JNHK and 3JNHCL coupling constants were used as
inputs for the rMD calculations. 3JNHCL coupling constants
were measured only for nepadutant because of the high con-
centrations necessary for the HETLOC experiment [15]. The
NH^HL crosspeaks of Trp3 and Leu6 show valuable coupling
patterns for the determination of 3JNHCL coupling constants,
2.0 Hz for Trp3 and 2.6 Hz for Leu6.
The results obtained by the MD re¢nement of the peptide
moiety of nepadutant and its by-products revealed a double L-
turn arrangement with Trp and Leu in position i+1 of a stan-
dard turn structure. Speci¢cally, a LI-turn in the Asp-Trp-
Phe-Dpr and a LII-turn in the Dpr-Leu-Asn-Asp regions
were observed. The ¢nal seven lowest energy structures belong
to one conformational family (Fig. 2). These structures all
converged to a similar backbone-fold within the range of 12
kJ mol31. Further restriction of the cyclic peptide backbone
through the additional side chain^side chain linkage probably
produces a very stable conformation and causes only few
£uctuations during the molecular dynamic simulation. Ap-
proximately 85% of the conformations of the last 30 ps tra-
jectories show the typical hydrogen pattern of a double L-turn
arrangement.
The arrangement of the Trp3 and Phe4 side chains is notice-
Table 1
1H-NMR chemical shifts, coupling constants and vN/vT values for the peptide moiety of nepadutant, as well as chemical shifts and coupling
constants for the sugar moieties of nepadutant and the by-products in DMSO-d6
Nepadutant amino acid
(333 K)
NNH (ppm) NHK (ppm) NHL0 (ppm) NHL (ppm) 3JNHK (Hz) 3JHKHL0 (Hz) 3JHKHL (Hz) vN/vT (ppb K31)
Asn1 8.81 4.36 2.94 2.21 6.4 6.0 5.9 4.8
Asp2 7.26 4.55 2.87S 2.65R 6.8 4.2 4.1 0.3
Trp3 8.58 4.17 2.87S 2.74R 3.8 9.5 4.2 5.3
Phe4 7.99 4.47 3.29S 2.60R 7.7 5.6 8.8 1.2
Dpr5 6.99 4.43 3.97S 3.54R 6.5 2.4 2.4 0.4
Leu6 8.35 4.09 1.52S 1.40R 5.0 8.9 5.5 4.4
Sugar moiety (298 K) NC1H NC2H NC3H NC4H NC5H NC6H 3JN1HÿC1H 3JN2HÿC2H
NC6H0 NO3H NO4=5H NO6H NN1H NN2H 3JC1HÿC2H 3JC2HÿC3H
Nepadutant 4.81 3.50 3.28 3.04 3.06 3.42 9.0 8.9
3.65 4.94 4.98 4.51 8.09 7.75 9.4 9.6
MEN11420A 5.02 4.07 3.46 3.29 3.09 3.48 8.9 9.5
3.65 4.77 4.79 4.35 8.05 7.15 1.2 4.4
MEN11420C 5.26 3.87 3.89 3.62 3.72 3.35 9.1 7.3
3.55 5.20 4.61 4.41 8.22 8.18 3.1 n.d.
MEN11420D 5.35 3.78 3.57 3.19 3.35 3.47 9.3 8.8
3.52 4.83 5.06 4.42 8.30 7.09 4.9 11.0
n.d. = not determined.
Table 2
Comparison of the experimental (NOESY) and calculated (rMD) backbone interproton distances of nepadutant
Proton pair rNOE rMD Proton pair rNOE rMD
Asn1NH Asp2NH 2.5 2.61 Asp2NH Asp2HLR 2.9 3.05
Asp2NH Dpr5NH 3.2 3.50 Trp3NH Asp2HLS 3.0 2.87
Asp2NH DprSCNH 3.3 3.19 Trp3NH Trp3HLS 2.8 3.00
Trp3NH Phe4NH 3.7 3.12 Trp3NH Trp3HLR 2.4 2.35
Phe4NH Dpr5NH 2.8 2.85 Phe4NH Trp3HLS 2.5 2.35
Dpr5NH DprSCNH n.d. 3.73 Phe4NH Phe4HLR 2.6 2.69
Leu6NH DprSCNH 2.3 2.45 Phe4NH Phe4HLS 3.4 3.74
DprSCNH Dpr5HLR 2.7 2.71
Asn1NH Leu6HK 2.3 2.19 DprSCNH Dpr5HLS 2.7 2.94
Asp2NH Leu6HK 3.8 3.34 DprSCNH Dpr5HLR 2.4 2.29
Trp3NH Asp2HK 2.1 2.36 Leu6NH Dpr5HLR 2.3 1.95
Phe4NH Trp6HK 3.2 3.60 Leu6NH Dpr5HLS 3.5 3.49
Dpr5NH Phe3HK 2.8 3.02 Leu6NH Leu6HLS 2.4 2.49
Leu6NH Dpr5HK 2.6 2.75 Leu6NH Leu6HLR 2.5 2.68
SC = side chain.
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able in addition to the backbone conformation. Several me-
dium range NOEs between the two ring systems are observ-
able. These NOEs lead to a parallel arrangement of the phenyl
and indolyl rings. Further con¢rmation was obtained by anal-
ysis of the homonuclear coupling constants 3JHKHL (Table 1).
It was possible to demonstrate conclusively the predominance
of the g2t3 rotamer (M1 = 180‡) and t2g3 rotamer (M1 =360‡)
for Trp3 and Phe4, respectively. This result is important be-
cause the dipeptide sequence Trp^Phe is intrinsic to the drug’s
site of action in the binding interactions with the tachykinin
NK2 receptor [16].
The 3JHKHL coupling constants for Asp2 and Dpr5 assume
low values (about 2 and 4 Hz), indicating the preference of a
staggered conformation with M1 = 60‡. This less preferred ori-
entation of the side chains permits the additional stabilization
of the two L-turns by the formation of further hydrogen
bonds, DprSCNHCLeu6CO and AspSCCOCPhe3NH (vN/
vT for DprSCNH 0.5 ppb K31 and Phe3NH 1.2 ppb K31).
3.4. Structural analysis of the sugar moiety
Di¡erences in the chemical shifts of the protons of amino
acids have been found for the Asn1HL protons of nepadutant
and all by-products, thus supporting our assumption of di¡er-
ent neighboring sugar moieties. This is sustained by major
di¡erences in the chemical shifts of the sugar moiety (Table
1, Fig. 3). Furthermore, remarkable di¡erences were found for
the carbohydrate C1H coupling pattern. The 3J(C1H^N1H)
coupling has been found with about 9 Hz in all cases. In
contrast, values between 1 and 9 Hz were observed for the
vicinal coupling 3J(C1H^C2H) (Table 1). The uniform
3J(C1H^N1H) couplings directed to the peptide core and the
di¡erent couplings 3J(C1H^C2H) directed to the carbohydrate
structure are caused by K- or L-glycosidic linkage and sterical
di¡erences at the C2 position of the carbohydrate moiety.
In the COSY spectra, the typical spin system of a pyranose
structure was found for nepadutant, MEN11420A and
MEN11420D. In contrast to these data, the spin system of
the sugar moiety di¡ers in positions 4C^6C for MEN11420C.
This spin system pattern con¢rms a furanose structure for
MEN11420C (Fig. 3).
Structure elucidation of the sugar moieties of nepadutant
and its by-products can be summarized as follows: nepadu-
tant shows a transoid orientation of the two acetamido
groups. This ¢nding, and the intermediate temperature coef-
¢cient of the NH at C2, suggest the occurrence of a C7 H-
bound Q-turn-like structure, and corresponds with NMR stud-
ies on a variety of N-glycopeptide models [17]. NMR studies
on MEN11420A demonstrate the L-linkage of 2-acetamido-
2-deoxy-D-mannopyranose on Asn1. The by-product
MEN11420A is a consequence of the impurity L-D-mannopyr-
anosylamine in L-D-glucopyranosylamine as a starting materi-
al in the last step of synthesis. For MEN11420C, investiga-
tions show the L-linkage of 2-acetamido-2-deoxy-L-D-
glucofuranose on Asn1. Chemical shifts and couplings of
MEN11420D demonstrate the K-glycosidic linkage of the sug-
ar moiety 2-acetamido-2-deoxy-D-glucopyranose on Asn1. The
by-products MEN11420C and MEN11420D are caused by the
phenomenon of mutarotation during amination of 2-acetami-
do-2-deoxy-D-glucopyranose via an open chain intermediate
and ¢nally cyclization to K-D-glucopyranosamine or L-D-glu-
cofuranosamine.
We can summarize, that the by-products pro¢le is charac-
terized by the occurrence of two detectable mutarotation
products, MEN11420C and MEN11420D, populated corre-
sponding to the ratio of mutarotation products of N-acetyl
glucosamine. Another type of hexose derivative would result
in a di¡erent by-product pro¢le. The by-product
MEN11420A is caused by impurity 2-acetamido-2-deoxy-L-
D-mannopyranosylamine in L-D-GlcNAc, which is coextracted
during the isolation of L-D-GlcNAc from chitin.
Fig. 2. Stereoplot of the LI, LII conformation of nepadutant. Oxygen atoms are indicated by ¢lled circles, nitrogen atoms are hatched. The P,
i, and M1 angles of the lowest energy conformations of the peptidic moiety of nepadutant and its by-products were determined. Asn1 : P= 68‡,
i= 7‡, M1 = n.d.; Asp2 : 3140, 157, 60; Trp3 : 348, 354, 180; Phe4 : 3101, 28, 360; Dpr5 : 3167, 3164, 60 and Leu6 : 375, 126, 180.
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4. Discussion
The synthesis and conformational analysis of constrained
analogues of native peptides has emerged as a very powerful
approach in peptide drug design [18]. A drastic reduction of
conformational space in peptide molecules is achieved by
backbone cyclization. In the case of the reported new NK2
receptor antagonist nepadutant discussed here, a further re-
duction of the conformational space was achieved by an addi-
tional side chain^side chain linkage. This further constraint
divides the peptide molecule into two parts. Each of these
parts forms a L-turn, where the two linkage-building amino
acids Asp2 and Dpr5 belong to both L-turns, and form the
characteristic hydrogen bonds. In the homochiral cyclic hexa-
peptide unit, we found a LI, LII-turn conformation. Here, the
arrangement of the side chain^side chain bridge ¢xes the
orientation of the amide bonds centered in the turns. There-
fore, the known LI/LII £ip found in many analyzed homochi-
ral L-turns is not observed [19]. Interestingly, such a dynamic
switch between LI/LII-turns was also observed in an glycosy-
lated cyclic peptide near the glycosylation site [20]. The bicy-
clic peptide design prevents the often described C2 symmetric
conformation of cyclic hexapeptides [21]. In our design the
Trp^Phe sequence was exposed in well de¢ned spatial arrange-
ments. The formation of a hydrophobic sandwich or cluster of
the indolyl and phenyl rings within the active dipeptide se-
quence Trp^Phe is noticeable. The homochiral hydrophobic
cluster formation over a trans peptide bond was also observed
Fig. 3. 1H-NMR spectra of nepadutant and MEN11420A^D in the range of the anomer sugar protons and HK protons of the amino acids at
298 K (right). The amino acid protons are extensively masked at this temperature. The structures of the associated sugar moieties and the de-
tected interproton distances (NOEs, dashed lines) are shown left.
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in other peptides [22,23]. Such a hydrophobic sandwich is
conceivable as a docking site for the receptor binding.
While the conformational requirements for the biological
activity are ful¢lled by the bicyclic peptide design, the require-
ments for clinical use are not met by the pure peptide. Nepa-
dutant has been developed due to the extremely poor water
solubility of the pure peptide MEN10627. The majority of
naturally occurring proteins are glycosylated, and the variety
of linkages between reducing sugar and proteins is enormous
[24]. The common structure of N-linked glycoproteins consists
of a pentasaccharide core with N-acetylglucosamine aspara-
gine linkage. The bicyclic glyco-hexapeptide nepadutant was
synthesized accordingly by coupling of L-D-GlcNAc-NH2 with
the aspartic acid of the bicyclic peptide precursor MEN11282.
NMR analyses with N-glycopeptides have suggested that the
polypeptide and the oligosaccharide have little mutual e¡ect
on local conformations [17].
The characterization of the by-products of nepadutant
show that no real contamination occurs. In fact, the natural
process of mutarotation of glucose is frozen by the linkage of
the glucose and peptide moiety. The process of mutarotation
does not occur in the glycopeptide, in such a way as to enable
us to separate and measure the single components. Although
there is no way to avoid the formation of MEN11420A, -C
and -D, but the by-products resulting from the mutarotation
are uncritical.
This investigation indicates the continued importance of
conformationally constrained antagonist molecules for the de-
sign of potent lead structures in the development of drugs.
Here, the conformational rigidity increases potency, speci¢city
and the hal£ife of the molecule in the living body. It can be
assumed that an increase of the activity is accessible by further
restrictions of the conformational space, for example by non-
peptidic L-turn mimetics.
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